

腫瘍内科学教室

近年の主な業績

1. Okano N, Mizutani T, Hironaka S : Promising Objective Response Rates and Progression-Free Survival but Modest Overall Survival in the TAB Study. *J Clin Oncol*. 2024 May 10;42(14):1726-1727. doi: 10.1200/JCO.23.02726.
2. Wakatsuki T, Ishizuka N, Hironaka S, Minashi K, Kadowaki S, Goto M, Shoji H, Hirano H, Nakayama I, Osumi H, Ogura M, Chin K, Yamaguchi K, Takahari D : Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab. *Int J Clin Oncol*. 2024 Jun;29(6):801-812. doi: 10.1007/s10147-024-02509-z.
3. Hashimoto T, Nakamura Y, Komatsu Y, Yuki S, Takahashi N, Okano N, Hirano H, Ohtsubo K, Ohta T, Oki E, Nishina T, Yasui H, Kawakami H, Esaki T, Machida N, Doi A, Boku S, Kudo T, Yamamoto Y, Kanazawa A, Denda T, Goto M, Iida N, Ozaki H, Shibuki T, Imai M, Fujisawa T, Bando H, Naito Y, Yoshino T: Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors. *BJC Rep*. 2024 Jul 25;2(1):54
4. Shibayama T, Hayashi A, Toki M, Kitahama K, Ho YJ, Kato K, Yamada T, Kawamoto S, Kambayashi K, Ochiai K, Gondo K, Okano N, Melchor JP, Iacobuzio-Donahue CA, Sakamoto Y, Hisamatsu T, Shibahara J: Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma. *Sci Rep*. 2024 Jul 6;14(1):15598.
5. Yoshikawa T, Kikko Y, Makino R, Kimijima Y, Nishiyama E, Matsuda Y, Casaes Teixeira B, Tejada M, Carroll R, Hironaka S : Adjuvant and post-recurrent treatment patterns in patients with resectable gastric cancer in Japan: a retrospective database cohort study. *Gastric Cancer*. 2024 Jul;27(4):827-839. doi: 10.1007/s10120-024-01501-w.

6. Ikeda M, Hijioka S, Ito T, Matsumoto S, Honma Y, Ueno M, Okano N, Aoki T, Furuse J. Multicenter validation study of a treatment selection MAP for pancreatic neuroendocrine tumors. *Jpn J Clin Oncol*. 2024 Aug 14; 54(8):880-886.
7. Takashima A, Hamaguchi T, Mizusawa J, Nagashima F, Ando M, Ojima H, Denda T, Watanabe J, Shinozaki K, Baba H, Asayama M, Hasegawa S, Masuishi T, Nakata K, Tsukamoto S, Katayama H, Nakamura K, Fukuda H, Kanemitsu Y, Shimada Y; Colorectal Cancer Study Group in Japan Clinical Oncology Group (JCOG). Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018). *J Clin Oncol*. 2024 Aug 26; JCO2302722. doi: 10.1200/JCO.23.02722.
8. Furuse J, Ikeda M, Ueno M, Furukawa M, Morizane C, Takehara T, Nishina T, Todaka A, Okano N, Hara K, Nakai Y, Ohkawa K, Sasaki T, Sugimori K, Yokoyama N, Yamamoto K:Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy. *Clin Cancer Res*. 2024 Sep 13; 30(18):3990-3995, 2024.
9. Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, Ikeda M, Sasaki M, Furuse J, Okano N, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T:Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. *J Clin Oncol*. 2024 Sep 20; 42(27):3207-3217.
10. Imaoka H, Sasaki K, Machida R, Nagano H, Satoi S, Ikeda M, Kobayashi S, Yamashita T, Okusaka T, Ido A, Hatano E, Miwa H, Ueno M, Nakao K, Shimizu S, Kuramochi H, Sakamori R, Tsumura H, Okano N, Shioji K, Shirakawa H, Akutsu N, Tsuji K, Ishii H, Umemoto K, Asagi A, Ueno M; JCOG Hepatobiliary and Pancreatic Oncology Group:Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22. *Jpn J Clin Oncol*. 2024 Oct 3; 54(10):1071-1077.
11. Ueno M, Morizane C, Ikeda M, Ozaka M, Nagashima F, Kataoka T, Mizusawa J, Ohba A, Kobayashi S, Imaoka H, Kasuga A, Okano N, Nagasaka Y, Sasaki M, Furuse J, Okusaka T : Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract

cancer (JCOG1808/NCCH1817, SNIPE). ESMO Open. 2024 Oct; 9(10):103919.

12. Sudo K, Nakamura Y, Ueno M, Furukawa M, Mizuno N, Kawamoto Y, Okano N, Umemoto K, Asagi A, Ozaka M, Ohtsubo K, Shimizu S, Matsuhashi N, Itoh S, Matsumoto T, Satoh T, Okuyama H, Goto M, Hasegawa H, Yamamoto Y, Odegaard JI, Bando H, Yoshino T, Ikeda M, Morizane C: Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Br J Cancer. 2024 Oct;131(7):1237-1245.
13. Takashima A, Ishiguro M, Sasaki K, Machida R, Nagashima F, Imaizumi J, Hamaguchi T, Yamamoto Y, Masuishi T, Asayama M, Ueno H, Shinozaki K, Kudo T, Machida N, Matsuoka H, Ishida H, Yamaguchi T, Nogami H, Yamada T, Takegawa N, Kito Y, Tonoike Y, Sawada R, Tsukamoto S, Kanemitsu Y: Colorectal Cancer Study Group (CCSG) of the Japan Clinical Oncology Group (JCOG). Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group. Jpn J Clin Oncol. 2024 Oct 3;54(10):1107-1114.
14. Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama S, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T: The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine. Cancer Discov. 2024 Nov 1; 14(11):2243-2261.
15. Shoji H, Kudo-Saito C, Nagashima N, Imazeki H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Muro K, Aoki K, Boku N : Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study). J Immunother Cancer. 2024 Nov 3;12(11):e010174.
16. Okano N, Kawai M, Ueno M, Yu X, Inoue Y, Takahashi S, Wang W, Takahashi H, Okamura Y, Morinaga S, Matsumoto I, Shimizu Y, Yoshida K, Yamamoto T, Ohtsuka M, Inokawa Y, Nara S, Tamura J, Shinoda S, Yamamoto K, Yamaue H, Furuse J : PC-CURE-1 study group. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-

- 1). J Hepatobiliary Pancreat Sci. 2024 Nov; 31(11):816-829.
17. Mitsunaga S, Ikeda M, Nomura S, Morizane C, Todaka A, Yamamoto N, Kamata K, Yanagibashi H, Mizuno N, Kawamoto Y, Gotoh K, Shirakawa H, Okano N, Nomura T, Tanaka K, Takahashi A, Yagi S, Ohta K, Takayama Y, Miwa H, Nagano H, Kojima Y, Hisano T, Tahara M, Sakuma Y, Arai H, Nakamura I, Katayama H, Konishi M, Ueno M; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG - HBPOG). 5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1). J Hepatobiliary Pancreat Sci. 2024 Dec; 31(12):886-896.
18. Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, Taniguchi H, Sunakawa Y, Yamaguchi K, Kato K, Denda T, Nishina T, Takahashi N, Satoh T, Yasui H, Satake H, Oki E, Kato T, Ohta T, Matsushashi N, Goto M, Okano N, Ohtsubo K, Yamazaki K, Yamashita R, Iida N, Yuasa M, Bando H, Yoshino T: Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors. Nat Med. 2025 Jan; 31(1):165-175.
19. Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, Tsumura H, Kimura N, Kawaguchi S, Kawamoto Y, Nakachi K, Tsuji K, Kobayashi N, Ashida R, Okano N, Umemoto K, Murohisa G, Hosokawa A, Asagi A, Nebiki H, Suzuki R, Terashima T, Shibata R, Kawata K, Doi T, Ohyama H, Kitano Y, Shioji K, Okuyama H, Naganuma A, Negoro Y, Sakamoto Y, Shimizu S, Morizane C, Ueno M, Furuse J, Nagano H; Japan Oncology Network in Hepatobiliary and Pancreas : Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting. J Gastroenterol. 2025 Mar; 60(3):356-367.
20. Komori A, Hironaka S, Kadowaki S, Mitani S, Furuta M, Kawakami T, Makiyama A, Takegawa N, Sugiyama K, Hirano H, Ando T, Matsushima T, Chida A, Kashiwada T, Komoda M, Matsumoto T, Oda H, Yabusaki H, Kawakami H, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K : West Japan Oncology Group (WJOG). Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS. Gastric Cancer. 2025 Mar; 28(2):301-308. doi:10.1007/s10120-024-01579-2.

21. Nishioka M, Okano N, Wakabayashi M, Ikeno T, Hayashi M, Mizutani T, Nagashima F, Furuse J : A retrospective study of gemcitabine plus nab-paclitaxel for advanced pancreatic cancer refractory to gemcitabine monotherapy. *Anticancer Res.* 44(3). 1233-1239. 2024.
22. Yoshikawa T, Kikko Y, Makino R, Kimijima Y, Nishiyama E, Matsuda Y, Cases Teixeira B, Tejada M, Carroll R, Hironaka S. Adjuvant and post-recurrent treatment patterns in patients with resectable gastric cancer in Japan: a retrospective database cohort study. *Gastric Cancer.* 2024. doi: 10.1007/s10120-024-01501-w.
23. Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, Nishina T, Yasui H, Kanazawa A, Ando K, Horita Y, Goto M, Okano N, Moriwaki T, Satoh T, Tsuji A, Yamashita K, Asano C, Abe Y, Nomura S, Yoshino T : Plasma angiogenic factors as predictors of the efficacy of second-line chemotherapy combined with angiogenesis inhibitors in metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit Study. *Clin Colorectal Cancer* 2024 Jan 18:S1533-0028(24)00003-3. doi: 10.1016/j.clcc.2024.01.003.
24. Okano N, Matsuki R, Toki M, Gondo K, Ochiai K, Watanabe S, Tateishi H, Kogure M, Suzuki Y, Sugiyama M, Nagashima F, Shibahara J, Sakamoto Y, Furuse J. A prospective study of neoadjuvant gemcitabine plus nab-paclitaxel in patients with borderline-resectable pancreatic cancer. *Intern Med.* 2023;62(3):327-334.
25. Kitamura H, Nakazawa J, Nagashima F, Andou M, Furuse J (Department of Medical Oncology, Kyorin University School of Medicine) : The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Study. *Intern Med.* 62(11). 1573-1580.2023.
26. Okuyama A, Mizutani T, Tachibana K, Higashi T, Ogawa A : Treatment Patterns and Postoperative Activities of Daily Living in Patients with Non-small Cell Lung Cancer: A Retrospective Study Using Nationwide Health Services Utilization Data in Japan. *Ann Surg Oncol.* 31(5). 3409-3416. 2023.
27. Matsuoka A, Mizutani T, Kaji Y, Yaguchi-Saito A, Odawara M, Saito J, Fujimori M, Uchitomi Y, Shimazu T : Barriers and facilitators to implementing geriatric assessment in daily oncology practice in Japan: A qualitative study using an

implementation framework. *J Geriatr Oncol.* 14(8). 101625. 2023.

28. Takei H, Kunitoh H, Wakabayashi M, Kataoka T, Sekino Y, Mizutani T, Tsuboi M, Ikeda N, Asamura H, Okada M, Takahama M, Ohde Y, Okami J, Shiono S, Aokage K, Watanabe SI : Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group, Japan. Prospective, Multi-Institutional Observational Study of Deterioration in Activities of Daily Living in Elderly Patients After Lung Cancer Surgery. *JTO Clin Res Rep.* 4(8). 100550. 2023.
29. Okano N, Matsuki R, Toki M, Gondo K, Ochiai K, Watanabe S, Tateishi H, Kogure M, Suzuki Y, Sugiyama M, Nagashima F, Shibahara J, Sakamoto Y, Furuse J : A prospective study of neoadjuvant gemcitabine plus nab-paclitaxel in patients with borderline-resectable pancreatic cancer. *Intern Med.* 62(3). 327-334. 2023.
30. Hironaka S, Sadachi R, Machida N, Iwasa S, Yamada Y, Sasako M, Yoshikawa T, Boku N, Terashima M. Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013. *Jpn J Clin Oncol.* 2022;52(1):14-23.
31. Imai M, Nakamura Y, Denda T, Komatsu Y, Yuki S, Nishina T, Hamamoto Y, Hara H, Esaki T, Kawakami H, Kato K, Satoh T, Okano N, Sunakawa Y, Taniguchi H, Yamaguchi K, Yamada T, Miki I, Wakabayashi M, Kuwata T, Shitara K, Yoshino T : Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis. *ESMO Gastrointestinal Oncology* 2023. 2023.
32. Nagashima F, Furuse J. Treatments for elderly cancer patients and reforms to social security systems in Japan. *Int J Clin Oncol.* 2022;27(2):310-315.
33. Mizutani T. Practical management of older adults with cancer: geriatric oncology in Japan. *Jpn J Clin Oncol.* 2022;52(10):1073-1081.
34. Komatsu Y, Hironaka S, Tanizawa Y, Cai Z, Piao Y, Boku N. Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study. *Adv Ther.* 2022 Jan;39(1):296-313.